Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
graft-versus-host disease
Biotech
MaaT posts 18-month data showing 'clear OS advantage' in aGvHD
The microbiome biotech has touted long-term data as proof it’s on track to launch the drug in acute graft-versus-host disease in two years’ time.
James Waldron
Apr 15, 2024 7:05am
Ironwood spies new frontier for $1B drug in exploratory trial
Mar 28, 2024 9:00am
BioSenic plots path past biotech graveyard and into phase 3
Oct 25, 2023 10:31am
Mesoblast plots path to market for twice-rejected cell therapy
Sep 21, 2023 6:45am
2nd time unlucky for Mesoblast as FDA rejects cell therapy
Aug 4, 2023 8:17am
FDA drops resistance to fecal pooling, clears MaaT for phase 3
Apr 24, 2023 6:10am